1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮
1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮
1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 性质
| 储存条件 | under inert gas (nitrogen or Argon) at 2-8°C |
|---|---|
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 用途与合成方法
Nothofagin pre-treatment (0.1, 1, 10 μM) decreases the level of histamine release in RBL-2H3 and RPMCs cells. The production of cytokines are downregulated bynothofagin pre-treatment Nothofagin (TNF-α: 1-10 μM; IL-4: 0.1-10 μM, IL-6: 1-10 μM).
Pre-treatment of DNPHSA-stimulated RBL-2H3 with Nothofagin (10 μM) markedly suppresses the phosphorylation of Lyn, Syk, and Akt.
Nothofagin (30 μM; for 6 hours) results in inhibited formation of LPS-induced (100 ng/mL; 4 hours) paracellular gaps with the formation of dense F-actin rings in HUVECs.
Nothofagin suppresses IgE-mediated mast cell degranulation both in vitro and in vivo.
Nothofagin (1 mg/kg; orally; once a day; for 7 days) significantly increases the urinary volume of both normotensive (NTR) and spontaneously hypertensive rats (SHR).
| Animal Model: | Male Wistar normotensive and spontaneously hypertensive rats (3-4 months old) |
| Dosage: | 1 mg/kg |
| Administration: | Orally; once a day; for 7 days |
| Result: | Significantly increased the urinary volume of both NTR and SHR. |
1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-02-08 | HY-113919 | 1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 | 11023-94-2 | 1 mg | 5819 |
| 2023-03-20 | HY-113919 | 1-(3-BETA-D-吡喃葡萄糖基-2,4,6-三羟基苯基)-3-(4-羟基苯基)-1-丙酮 | 11023-94-2 | 5mg | 12500 |
